SBIR/STTR Research Award

TK/ AND CHO HGPRT AND TK/ SUSPENSION ASSAYS THE MAJOR OBJECTIVE OF THIS STUDY IS TO IMPROVE THE ABILITY OF THE L5178Y TK/ ASSAY TO ESTIMATE THE MUTAGENIC POTENTIAL OF TEST COMPOUNDS.

Award identifier bfb72fd4b8e0c6c64805543df7e6cb0672b954f182c946bd61b58ad6640f303fAwarding agency Department of Health and Human Services

Award amount

$50,000

Program and phase

SBIR · Phase I

Award year

1985

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
Sitek Research Laboratories
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

TK/ AND CHO HGPRT AND TK/ SUSPENSION ASSAYS THE MAJOR OBJECTIVE OF THIS STUDY IS TO IMPROVE THE ABILITY OF THE L5178Y TK/ ASSAY TO ESTIMATE THE MUTAGENIC POTENTIAL OF TEST COMPOUNDS. SPECIFICALLY, MUTATION AT THE TK LOCUS OF L5178Y CELLS WILL BE COMPARED TO MUTATION AT THE HGPRT AND TK LOCI OF CHO CELLS TO DETERMINE IF THE TK/ TO TK/ MUTATION IN L5178Y CELLS IS REPRESENTATIVE OF MAMMALIAN GENE MUTATIONS. IN ADDITION, DISCREPANCIES BETWEEN EXISTING L5178Y AND RODENT CHRONIC STUDY RESULTS WILL BE EVALUATED AND AN ATTEMPT WILL BE MADE TO IMPROVE THE CORRELATION. AT THE END OF PHASE I: 1. SEVERAL POSITIVE AND NEGATIVE COMPOUNDS WILL HAVE BEEN SIMULTANEOUSLY TESTED IN THE L5178Y AND CHO SUSPENSION ASSAY, 2. A CHO TK/ HETEROZYGOTE WILL HAVE BEEN ISOLATED AND EVALUATED FOR NORMAL KARYOTYPE, LOW SPONTANEOUS 3. DISCREPANT RESULTS BETWEEN L5178Y ASSAY AND CHRONIC PHASE II STUDIES WILL CONSIST OF: 1. 2. SIMULTANEOUSLY TESTING COMPOUNDS IN THE L5178Y TK/ ASSAY AND CHO HGPRT AND TK/ ASSAYS, AND3. PERFORMING ADDITIONAL L5178Y ASSAYS ON TEST COMPOUNDS THAT GAVE DISCREPANT RESULTS BETWEEN THE L5178Y AND CHRONIC RODENT STUDIES. THIS PROJECT WILL BE INVALUABLE IN RE-ESTABLISHING THE L5178Y ASSAY AS CREDIBLE AND INDICATIVE OF GENE MUTATIONS. IN ADDITION, THE DEVELOPMENT OF A SECOND CELL LINE (CHO TK/) HAVING A SIMILAR ENDPOINT AND SHORT EXPRESSION PERIOD WILL BE A USEFUL TOOL FOR EVALUATING CHEMICALS FOR MUTAGENIC POTENTIAL.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.